Cover Image

LEADER Trial: Liraglutide reduces mortality in patients with type 2 diabetes. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016 [Epub ahead of print].

Fuente: Redalyc

Saved in:

Bibliographic Details
Main Author:	Jorge Thierer
Format:	Artículo científico
Language:	en
Published:	Sociedad Argentina de Cardiología 2016
Subjects:	Medicina
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction
by: Qianyi Li, et al.
Published: (2024)

A Novel Method for Liraglutide Synthesis and Purification
by: Gabriela R. Barredo‐Vacchelli, et al.
Published: (2024)

Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18‐month follow‐up of a randomized clinical trial
by: Paola Caruso, et al.
Published: (2025)

Neuroprotective Effects of Liraglutide and/or Rivastigmine Combination on the Rat Hippocampus
by: Raafat A. Abdel‐Aal, et al.
Published: (2025)

The Anti‐Inflammatory Effects of Liraglutide in Equine Inflammatory Joint Models
by: Ann‐Sofie Scheike, et al.
Published: (2025)

Liraglutide results in significant weight loss in patients with bipolar disorder
Published: (2024)

Prognostic models for all‐cause and cardiovascular mortality in type 2 diabetes: Systematic review
by: Monica Kundu, et al.
Published: (2026)

Differential impacts of fat and muscle mass on cardiovascular and non‐cardiovascular mortality in individuals with type 2 diabetes
by: Jie Guo, et al.
Published: (2024)

Effect of GLP‐1RA on mortality and cardiovascular risk in adults with psoriasis and type 2 diabetes
by: Claire Lin, et al.
Published: (2026)

The Impact of Liraglutide on Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
by: Jae Eun So, et al.
Published: (2025)

A decade of SGLT2 inhibitors: Lessons learned and the road ahead in type 2 diabetes
by: Tomohiko Kimura, et al.
Published: (2025)

Serum T50 predicts cardiovascular mortality in individuals with type 2 diabetes: A prospective cohort study
by: Amarens van der Vaart, et al.
Published: (2024)

Effect of Liraglutide on Intermittent Hypoxia‐Induced Metabolic Dysfunction: From Bench to Bedside
by: Cliona O'Donnell, et al.
Published: (2025)

Trends in mortality and hospitalisations for cardiovascular, kidney and liver disease in people with type 2 diabetes in England, 2009–2019
by: Naomi Holman, et al.
Published: (2025)

Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5
by: Qian Zhang, et al.
Published: (2024)

Liraglutide for idiopathic intracranial hypertension: a real‐world propensity score‐matched study
by: Ahmed Y. Azzam, et al.
Published: (2025)

Liraglutide upregulates the Cftr gene and regulates the mucus transcriptome profile in Brunner's glands in mice
by: Louise Marie Voetmann, et al.
Published: (2025)

Arterial stiffness and atherosclerosis and incident cardiovascular events and all‐cause mortality in individuals with manifest cardiovascular disease with and without type 2 diabetes
by: Jan F. de Leijer, et al.
Published: (2025)

The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes
by: David R. Riley, et al.
Published: (2024)

Metformin lowers risk of hearing loss and mortality in type 2 diabetes
by: Chun‐Chih Huang, et al.
Published: (2024)

Impact of time in tight range on all‐cause and cardiovascular mortality in type 2 diabetes: A prospective cohort study
by: Jinghao Cai, et al.
Published: (2025)

Role of the peripheral chemoreceptors in cardiovascular and metabolic control in type 2 diabetes
by: Jacqueline K. Limberg, et al.
Published: (2024)

Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes
by: Montse Guardiola, et al.
Published: (2024)

Association between atherosclerotic cardiovascular disease risk and diabetic retinopathy in patients with type 2 diabetes mellitus
by: Chrysa Agapitou, et al.
Published: (2025)

Development And Validation Method for Estimation for Liraglutide By RP-HPLC From Its Injectable Dosage Form
by: Akhil Bhakhar*, Khyati Bhupta, Dhirendra Kumar Tarai, Dr. Santosh Kirtane
Published: (2025)

Naltrexone/Bupropion, Liraglutide, or Semaglutide as Adjuvant Therapy After Metabolic and Bariatric Surgery: An Observational Study
by: Anthony Brancatisano, et al.
Published: (2025)

Liraglutide Attenuates Disease Severity in Experimental Autoimmune Encephalomyelitis by Modulating Splenic T Helper Cell Subsets
by: Shuang Song, et al.
Published: (2025)

Increased cardiovascular risk in people with LADA in comparison to type 1 diabetes and type 2 diabetes: Findings from the DPV registry in Germany and Austria
by: Rosa C. Golomb, et al.
Published: (2024)

Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps
by: Duo Chen, et al.
Published: (2024)

Prognostic value of triglyceride‐derived metabolic parameters for micro‐ and macrovascular complications and mortality in individuals with type 2 diabetes: The Rio de Janeiro type 2 diabetes cohort study
by: Claudia R. L. Cardoso, et al.
Published: (2026)

Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes
by: Djordje S. Popovic, et al.
Published: (2024)

Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study
by: Haiyan Cheng, et al.
Published: (2026)

Assessment of Thermal and Photolytic Stress Effects on the Stability of Primary Structure of Synthetic Liraglutide Using LC‐HRMS/MS
by: Devendra Badgujar, et al.
Published: (2025)

A Validated, Stability‐Indicating HPLC Method for the Simultaneous Determination of Five Related Substances in Liraglutide Drug Substance
by: Lixiang Zhang, et al.
Published: (2025)

Prediction of heart failure as the first major cardiovascular disease event in type 2 diabetes
by: Julian W. Sacre, et al.
Published: (2026)

Monocyte–lymphocyte ratio predicts cardiovascular diseases death in individuals with type 2 diabetes
by: Han Li, et al.
Published: (2024)

Development and validation of a diabetes/nutrition knowledge questionnaire in type 1 and type 2 diabetes
by: Giulia Hofer, et al.
Published: (2025)

A reduced model for the long-term effects of physical activity on type 2 diabetes
by: Multerer, Lea, et al.
Published: (2024)

Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes
by: Mohmmad Alghamdi, et al.
Published: (2025)

Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study
by: Nora Hennies, et al.
Published: (2024)